Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Net Income data on record, last reported at $16.2 million in Q4 2025.

  • For Q4 2025, Net Income rose 597.45% year-over-year to $16.2 million; the TTM value through Dec 2025 reached -$12.6 million, up 32.16%, while the annual FY2025 figure was -$63.4 million, 241.01% down from the prior year.
  • Net Income reached $16.2 million in Q4 2025 per LCTX's latest filing, up from -$3.4 million in the prior quarter.
  • Across five years, Net Income topped out at $16.2 million in Q4 2025 and bottomed at -$19.3 million in Q2 2025.
  • Average Net Income over 5 years is -$5.4 million, with a median of -$6.0 million recorded in 2025.
  • Peak YoY movement for Net Income: crashed 389.85% in 2022, then surged 597.45% in 2025.
  • A 5-year view of Net Income shows it stood at -$8.8 million in 2021, then crashed by 38.28% to -$12.2 million in 2022, then surged by 61.46% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then soared by 597.45% to $16.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $16.2 million in Q4 2025, -$3.4 million in Q3 2025, and -$19.3 million in Q2 2025.